|
 The molnupiravir COVID-19 treatment pill for adult patients at risk
of developing severe illness was jointly developed by U.S.-based
Merck & Co Inc and Ridgeback Biotherapeutics.
The Southeast Asian nation intends to join other countries in the
region also planning to make versions of the drug including
Bangladesh and India.
"For molnupiravir, the Government Pharmaceutical Organization has
plans to co-develop (this drug) with the Chulabhorn Research
Institute," Minister Anutin Charnvirakul told a news conference.
"A committee will research and produce the reactants, which will be
additional support for future events," he said.
[to top of second column] |
 Separately, Indonesia's health
minister Budi Gunadi Sadikin said on Friday the
country also planned to develop molnupiravir in
partnership with pharmaceutical company PT.
Amarox Pharma Global starting in April or May.
Indonesia approved molnupiravir for emergency
use this week and 400,000 pills have arrived.
Thailand has ordered 50,000 courses of
molnupiravir from Merck and was still in
discussion with Pfizer for 50,000 courses of its
drug Paxlovid.
(Reporting by Panarat Thepgumpanat and Chayut
Setboonsarng in Bangkok and Stanley Widianto in
Jakarta; Editing by Ed Davies)
[© 2022 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
